Diagnostic yield of different screening protocols in 210 IAR of the FaPaCa cohort
| Screening protocol | N | IAR with pancreatic lesions | IAR with potentially relevant pancreatic lesions* | Missed PDAC |
|---|---|---|---|---|
| All IAR | 210 | 120 (57%) | 11 | 1 |
| IAR in protocol 1† | 98‡ | 47 (48%) | 5 | 0 |
| IAR in protocol 2§ | 175‡ | 73 (42%) | 6 | 0 |
| IAR with screening intervals ≥24 months | 30/210 (14.3%) | 17 (57%) | 1/30 (3%) | 1 |
*Includes PDAC, multifocal PanIN2/3 lesions with/without BD-IPMN or AFL, pNET.
†Protocol 1 included MRI+MRCP+EUS every 12 months.
‡63 IAR were also screened with the other protocol during the complete study time.
§Protocol 2 consisted of annual MRI+MRCP. EUS was performed at baseline and then every 3 years or in case of suspicious MRI findings.
AFL, atypical flat lesion; BD, branch duct; EUS, endoscopic ultrasonography; FaPaCa, the national case collection for familial pancreatic cancer in Germany; IAR, individuals at risk; IPMN, intraductal papillary mucinous neoplasia; MRCP, MR cholangiopancreatography; PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma; pNET, pancreatic neuroendocrine tumour.